Explore the words cloud of the ITCC-P4 project. It provides you a very rough idea of what is the project "ITCC-P4" about.
The following table provides information about the project.
Coordinator |
DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
Organization address contact info |
Coordinator Country | Germany [DE] |
Project website | https://www.itccp4.eu/ |
Total cost | 16˙562˙831 € |
EC max contribution | 7˙370˙000 € (44%) |
Programme |
1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2)) |
Code Call | H2020-JTI-IMI2-2015-07-two-stage |
Funding Scheme | IMI2-RIA |
Starting year | 2017 |
Duration (year-month-day) | from 2017-01-01 to 2021-12-31 |
Take a look of project's partnership.
Cancer remains the leading cause of disease-related death in children. For the ~25% of children who experience relapses of their malignant solid tumors, usually after very intensive first-line therapy, curative treatment options are scarce. Preclinical drug testing to identify promising treatment options that match the molecular make-up of the tumor is hampered by the facts that i) molecular genetic data on pediatric solid tumors from relapsed patients and thus our understanding of tumor evolution and therapy resistance are very limited to date and ii) for many of the high-risk entities no appropriate and molecularly well characterized patient-derived models and/or genetic mouse models are currently available. Thus, quality-assured upfront preclinical testing of novel molecularly targeted compounds in a (saturated) repertoire of well-characterized models will establish the basis to increase therapeutic successes of these drugs in children with solid malignancies. Since these tumors are overall genetically much less complex than their adult counterparts, it is anticipated that it will be easier to identify powerful predictive biomarkers to allow for accurate matching of targets and drugs.
To address this high, as yet unmet clinical need, we have formed the ITCC-P4 consortium consisting of academic and commercial partners from 8 European countries and covering the full spectrum of qualifications needed for quality-assured preclinical drug development including expertise in patient derived models, histopathology, in vivo pharmacology, bioinformatics and data management, centralized testing capabilities, medical expertise regarding the entities in question, regulatory knowledge, and project management of large consortia. With this consortium in a public-private partnership with the participating pharma companies we strongly believe to be ideally positioned to greatly expedite the development of more precise and efficacious drugs for children with malignant solid tumors
International scientific symposium on : “Preclinicalevaluation in pediatric oncology drug development†| Websites, patent fillings, videos etc. | 2020-04-08 23:48:21 |
Take a look to the deliverables list in detail: detailed list of ITCC-P4 deliverables.
year | authors and title | journal | last update |
---|---|---|---|
2019 |
Cinzia Zucchini, Maria Cristina Manara, Camilla Cristalli, Marianna Carrabotta, Sara Greco, Rosa Simona Pinca, Cristina Ferrari, Lorena Landuzzi, Michela Pasello, Pier-Luigi Lollini, Marco Gambarotti, Davide Maria Donati, Katia Scotlandi ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity published pages: , ISSN: 1756-9966, DOI: 10.1186/s13046-019-1506-3 |
Journal of Experimental & Clinical Cancer Research 38/1 | 2020-04-08 |
2019 |
Hannah Kohler, Soeren Latteyer, Georg Sebastian Hönes, Sarah Theurer, Xiao-Hui Liao, Sandra Christoph, Denise Zwanziger, Johannes H. Schulte, Jukka Kero, Hendrik Undeutsch, Samuel Refetoff, Kurt W. Schmid, Dagmar Führer, Lars C. Moeller Increased Anaplastic Lymphoma Kinase Activity Induces a Poorly Differentiated Thyroid Carcinoma in Mice published pages: 1438-1446, ISSN: 1050-7256, DOI: 10.1089/thy.2018.0526 |
Thyroid 29/10 | 2020-04-08 |
2019 |
Lisa Gabler, Daniela Lötsch, Dominik Kirchhofer, Sushilla van Schoonhoven, Hannah M. Schmidt, Lisa Mayr, Christine Pirker, Katharina Neumayer, Carina Dinhof, Lucia Kastler, Amedeo A. Azizi, Christian Dorfer, Thomas Czech, Christine Haberler, Andreas Peyrl, Rajiv Kumar, Irene Slavc, Sabine Spiegl-Kreinecker, Johannes Gojo, Walter Berger TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAFV600E/TERT promoter double-mutated glioma published pages: , ISSN: 2051-5960, DOI: 10.1186/s40478-019-0775-6 |
Acta Neuropathologica Communications 7/1 | 2020-04-08 |
2020 |
Natalie Timme, Youjia Han, Shuai Liu, Hailemichael O. Yosief, Heathcliff Dorado GarcÃa, Yi Bei, Filippos Klironomos, Ian C. MacArthur, Annabell Szymansky, Jennifer von Stebut, Victor Bardinet, Constantin Dohna, Annette Künkele, Jana Rolff, Patrick Hundsdörfer, Andrej Lissat, Georg Seifert, Angelika Eggert, Johannes H. Schulte, Wei Zhang, Anton G. Henssen Small-Molecule Dual PLK1 and BRD4 Inhibitors are Active Against Preclinical Models of Pediatric Solid Tumors published pages: 221-232, ISSN: 1936-5233, DOI: 10.1016/j.tranon.2019.09.013 |
Translational Oncology 13/2 | 2020-04-08 |
2019 |
Youjia Han, Sven Lindner, Yi Bei, Heathcliff Dorado Garcia, Natalie Timme, Kristina Althoff, Andrea Odersky, Alexander Schramm, Andrej Lissat, Annette Künkele, Hedwig E. Deubzer, Angelika Eggert, Johannes H. Schulte, Anton G. Henssen Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma published pages: 24-33, ISSN: 0304-3835, DOI: 10.1016/j.canlet.2018.12.012 |
Cancer Letters 445 | 2020-04-08 |
2018 |
Sebastian Brabetz, Sarah E. S. Leary, Susanne N. Gröbner, Madison W. Nakamoto, Huriye Şeker-Cin, Emily J. Girard, Bonnie Cole, Andrew D. Strand, Karina L. Bloom, Volker Hovestadt, Norman L. Mack, Fiona Pakiam, Benjamin Schwalm, Andrey Korshunov, Gnana Prakash Balasubramanian, Paul A. Northcott, Kyle D. Pedro, Joyoti Dey, Stacey Hansen, Sally Ditzler, Peter Lichter, Lukas Chavez, David T. W. Jones, Jan Koster, Stefan M. Pfister, Marcel Kool, James M. Olson A biobank of patient-derived pediatric brain tumor models published pages: 1752-1761, ISSN: 1078-8956, DOI: 10.1038/s41591-018-0207-3 |
Nature Medicine 24/11 | 2020-04-08 |
2018 |
Sebastian Brabetz, Susanne N. Gröbner, Natalie Jäger, Till Milde, Jonas Ecker, Florian Selt, Olaf Witt, Jessica M. Rusert, Jan Koster, Sarah E. Leary, Xiao-Nan Li, Robert J. Wechsler-Reya, James M. Olson, Stefan M. Pfister, and Marcel Kool A biobank of patient-derived molecularly characterized orthotopic pediatric brain tumor models for preclinical research published pages: , ISSN: , DOI: |
2020-04-08 | |
2018 |
Sebastian Brabetz Molecular and preclinical evaluation of patient-derived orthotopic xenograft models of pediatric brain tumors published pages: , ISSN: , DOI: |
2020-04-08 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ITCC-P4" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ITCC-P4" are provided by the European Opendata Portal: CORDIS opendata.
Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs
Read MoreProgress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
Read More